These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing. Schenerman MA; Hope JN; Kletke C; Singh JK; Kimura R; Tsao EI; Folena-Wasserman G Biologicals; 1999 Sep; 27(3):203-15. PubMed ID: 10652176 [TBL] [Abstract][Full Text] [Related]
23. In silico prediction of post-translational modifications in therapeutic antibodies. Vatsa S MAbs; 2022; 14(1):2023938. PubMed ID: 35040751 [TBL] [Abstract][Full Text] [Related]
24. Asparagine deamidation dependence on buffer type, pH, and temperature. Pace AL; Wong RL; Zhang YT; Kao YH; Wang YJ J Pharm Sci; 2013 Jun; 102(6):1712-1723. PubMed ID: 23568760 [TBL] [Abstract][Full Text] [Related]
25. An accelerated surface-mediated stress assay of antibody instability for developability studies. Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P MAbs; 2020; 12(1):1815995. PubMed ID: 32954930 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of the pattern and kinetics of degradation of adalimumab using a stability-indicating orthogonal testing protocol. Hassan LA; Al-Ghobashy MA; Abbas SS Biomed Chromatogr; 2019 Dec; 33(12):e4676. PubMed ID: 31389037 [TBL] [Abstract][Full Text] [Related]
27. Aggregation Time Machine: A Platform for the Prediction and Optimization of Long-Term Antibody Stability Using Short-Term Kinetic Analysis. Bunc M; Hadži S; Graf C; Bončina M; Lah J J Med Chem; 2022 Feb; 65(3):2623-2632. PubMed ID: 35090111 [TBL] [Abstract][Full Text] [Related]
28. Effects of antibody disulfide bond reduction on purification process performance and final drug substance stability. Chung WK; Russell B; Yang Y; Handlogten M; Hudak S; Cao M; Wang J; Robbins D; Ahuja S; Zhu M Biotechnol Bioeng; 2017 Jun; 114(6):1264-1274. PubMed ID: 28186329 [TBL] [Abstract][Full Text] [Related]
29. Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol. Mohamed HE; Mohamed AA; Al-Ghobashy MA; Fathalla FA; Abbas SS J Pharm Biomed Anal; 2018 Feb; 150():268-277. PubMed ID: 29258046 [TBL] [Abstract][Full Text] [Related]
30. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. Thirumangalathu R; Krishnan S; Ricci MS; Brems DN; Randolph TW; Carpenter JF J Pharm Sci; 2009 Sep; 98(9):3167-81. PubMed ID: 19360857 [TBL] [Abstract][Full Text] [Related]
31. Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy. Das TK; Narhi LO; Sreedhara A; Menzen T; Grapentin C; Chou DK; Antochshuk V; Filipe V J Pharm Sci; 2020 Jan; 109(1):116-133. PubMed ID: 31593689 [TBL] [Abstract][Full Text] [Related]
32. Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion. Wang Y; Li X; Liu YH; Richardson D; Li H; Shameem M; Yang X MAbs; 2016; 8(8):1477-1486. PubMed ID: 27598507 [TBL] [Abstract][Full Text] [Related]
33. Developability assessment during the selection of novel therapeutic antibodies. Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140 [TBL] [Abstract][Full Text] [Related]
34. Impact of mAb Aggregation on Its Biological Activity: Rituximab as a Case Study. Bansal R; Dash R; Rathore AS J Pharm Sci; 2020 Sep; 109(9):2684-2698. PubMed ID: 32473898 [TBL] [Abstract][Full Text] [Related]
35. Influence of pH on heat-induced aggregation and degradation of therapeutic monoclonal antibodies. Ishikawa T; Ito T; Endo R; Nakagawa K; Sawa E; Wakamatsu K Biol Pharm Bull; 2010; 33(8):1413-7. PubMed ID: 20686240 [TBL] [Abstract][Full Text] [Related]
36. Forced degradation of recombinant monoclonal antibodies: A practical guide. Nowak C; K Cheung J; M Dellatore S; Katiyar A; Bhat R; Sun J; Ponniah G; Neill A; Mason B; Beck A; Liu H MAbs; 2017; 9(8):1217-1230. PubMed ID: 28853987 [TBL] [Abstract][Full Text] [Related]
37. Effects of arginine on photostability and thermal stability of IgG1 monoclonal antibodies. Maity H; O'Dell C; Srivastava A; Goldstein J Curr Pharm Biotechnol; 2009 Dec; 10(8):761-6. PubMed ID: 19939215 [TBL] [Abstract][Full Text] [Related]
38. [Therapeutic antibodies: importance of galenics for efficacy and safety]. Manache L; Dulieu C; Boussif O Med Sci (Paris); 2009 Dec; 25(12):1063-9. PubMed ID: 20035680 [TBL] [Abstract][Full Text] [Related]
39. Establishment and validation of a microfluidic capillary gel electrophoresis platform method for purity analysis of therapeutic monoclonal antibodies. Smith MT; Zhang S; Adams T; DiPaolo B; Dally J Electrophoresis; 2017 May; 38(9-10):1353-1365. PubMed ID: 28211938 [TBL] [Abstract][Full Text] [Related]
40. Orthogonal Techniques to Study the Effect of pH, Sucrose, and Arginine Salts on Monoclonal Antibody Physical Stability and Aggregation During Long-Term Storage. Svilenov HL; Kulakova A; Zalar M; Golovanov AP; Harris P; Winter G J Pharm Sci; 2020 Jan; 109(1):584-594. PubMed ID: 31689429 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]